{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:08:05Z","timestamp":1787004485902,"version":"build-2736575974"},"reference-count":55,"publisher":"Portland Press Ltd.","issue":"2","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,4,15]]},"abstract":"<jats:p>Immunotherapy of cancer using chimeric antigen receptor (CAR) T-cells is a rapidly expanding field. CARs are fusion molecules that couple the binding of a tumour-associated cell surface target to the delivery of a tailored T-cell activating signal. Re-infusion of such genetically engineered T-cells to patients with haematological disease has demonstrated unprecedented response rates in Phase I clinical trials. However, such successes have not yet been observed using CAR T-cells against solid malignancies and this is, in part, due to a lack of safe tumour-specific targets. The \u03b1v\u03b26 integrin is strongly up-regulated in multiple solid tumours including those derived from colon, lung, breast, cervix, ovaries\/fallopian tube, pancreas and head and neck. It is associated with poorer prognosis in several cancers and exerts pro-tumorigenic activities including promotion of tumour growth, migration and invasion. By contrast, physiologic expression of \u03b1v\u03b26 is largely restricted to wound healing. These attributes render this epithelial-specific integrin a highly attractive candidate for targeting using immunotherapeutic strategies such as CAR T-cell adoptive immunotherapy. This mini-review will discuss the role and expression of \u03b1v\u03b26 in cancer, as well as its potential as a therapeutic target.<\/jats:p>","DOI":"10.1042\/bst20150249","type":"journal-article","created":{"date-parts":[[2016,4,11]],"date-time":"2016-04-11T05:57:10Z","timestamp":1460354230000},"page":"349-355","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["The integrin \u03b1v\u03b26: a novel target for CAR T-cell immunotherapy?"],"prefix":"10.1042","volume":"44","author":[{"given":"Lynsey\u00a0M.","family":"Whilding","sequence":"first","affiliation":[{"name":"King's College London, King's Health Partners Integrated Cancer Centre, Department of Research Oncology, Guy's Hospital, Great Maze Pond, London SE1 9RT, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabari","family":"Vallath","sequence":"additional","affiliation":[{"name":"Centre for Tumour Biology, John Vane Science Centre, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Maher","sequence":"additional","affiliation":[{"name":"King's College London, King's Health Partners Integrated Cancer Centre, Department of Research Oncology, Guy's Hospital, Great Maze Pond, London SE1 9RT, U.K."},{"name":"Department of Immunology, Barnet Hospital, Royal Free London NHS Foundation Trust, Barnet EN5 3DJ, U.K."},{"name":"Department of Clinical Immunology and Allergy, King's College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2016,4,11]]},"reference":[{"key":"2021111818114450200_B1","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"2021111818114450200_B2","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"2021111818114450200_B3","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"2021111818114450200_B4","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"2021111818114450200_B5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/PPO.0000000000000032","article-title":"CAR T cells for solid tumors: armed and ready to go?","volume":"20","author":"Kakarla","year":"2014","journal-title":"Cancer J."},{"key":"2021111818114450200_B6","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/j.molonc.2015.10.012","article-title":"CAR T-cell immunotherapy: The path from the by-road to the freeway?","volume":"9","author":"Whilding","year":"2015","journal-title":"Mol. Oncol."},{"key":"2021111818114450200_B7","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/mt.2009.133","article-title":"Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression","volume":"17","author":"Ahmed","year":"2009","journal-title":"Mol. Ther."},{"key":"2021111818114450200_B8","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"key":"2021111818114450200_B9","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"2021111818114450200_B10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/PPO.0000000000000035","article-title":"Managing cytokine release syndrome associated with novel T cell-engaging therapies","volume":"20","author":"Maude","year":"2014","journal-title":"Cancer J."},{"key":"2021111818114450200_B11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2174\/1566523213666131223130554","article-title":"Clinical immunotherapy of B-cell malignancy using CD19-targeted CAR T-cells","volume":"14","author":"Maher","year":"2014","journal-title":"Curr. Gene Ther."},{"key":"2021111818114450200_B12","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/mt.2013.17","article-title":"Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity","volume":"21","author":"Lamers","year":"2013","journal-title":"Mol. Ther."},{"key":"2021111818114450200_B13","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol. Ther."},{"key":"2021111818114450200_B14","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/mt.2010.42","article-title":"Safer CARS","volume":"18","author":"Heslop","year":"2010","journal-title":"Mol. Ther."},{"key":"2021111818114450200_B15","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"2021111818114450200_B16","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/(SICI)1521-1878(199906)21:6&lt;499::AID-BIES6&gt;3.0.CO;2-D","article-title":"Integrins: alternative splicing as a mechanism to regulate ligand binding and integrin signaling events","volume":"21","author":"de Melker","year":"1999","journal-title":"BioEssays"},{"key":"2021111818114450200_B17","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S0092-8674(02)00971-6","article-title":"Integrins: bidirectional, allosteric signaling machines","volume":"110","author":"Hynes","year":"2002","journal-title":"Cell"},{"key":"2021111818114450200_B18","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1242\/jcs.108.6.2241","article-title":"Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling","volume":"108","author":"Breuss","year":"1995","journal-title":"J. Cell Sci."},{"key":"2021111818114450200_B19","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1083\/jcb.133.4.921","article-title":"Inactivation of the integrin beta 6 subunit gene reveals a role of epithelial integrins in regulating inflammation in the lung and skin","volume":"133","author":"Huang","year":"1996","journal-title":"J. Cell Biol."},{"key":"2021111818114450200_B20","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1172\/JCI58815","article-title":"The alphavbeta6 integrin modulates airway hyperresponsiveness in mice by regulating intraepithelial mast cells","volume":"122","author":"Sugimoto","year":"2012","journal-title":"J. Clin. Invest."},{"key":"2021111818114450200_B21","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1002\/cbin.10258","article-title":"Alphavbeta6 is required in maintaining the intestinal epithelial barrier function","volume":"38","author":"Yu","year":"2014","journal-title":"Cell Biol. Int."},{"key":"2021111818114450200_B22","doi-asserted-by":"publisher","first-page":"4533","DOI":"10.1128\/JVI.78.9.4533-4540.2004","article-title":"Integrin alphavbeta8 functions as a receptor for foot-and-mouth disease virus: role of the beta-chain cytodomain in integrin-mediated infection","volume":"78","author":"Jackson","year":"2004","journal-title":"J. Virol."},{"key":"2021111818114450200_B23","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0092-8674(00)80545-0","article-title":"The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis","volume":"96","author":"Munger","year":"1999","journal-title":"Cell"},{"key":"2021111818114450200_B24","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1083\/jcb.127.2.547","article-title":"The alpha v beta 6 integrin promotes proliferation of colon carcinoma cells through a unique region of the beta 6 cytoplasmic domain","volume":"127","author":"Agrez","year":"1994","journal-title":"J. Cell Biol."},{"key":"2021111818114450200_B25","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1158\/0008-5472.CAN-07-2307","article-title":"Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in\u00a0vivo by a transforming growth factor-beta-regulated mechanism","volume":"68","author":"Van Aarsen","year":"2008","journal-title":"Cancer Res."},{"key":"2021111818114450200_B26","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccr.2009.03.022","article-title":"A gene expression signature associated with \"K-Ras addiction\" reveals regulators of EMT and tumor cell survival","volume":"15","author":"Singh","year":"2009","journal-title":"Cancer Cell"},{"key":"2021111818114450200_B27","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1046\/j.0022-202x.2001.01379.x","article-title":"Expression of the alphavbeta6 integrin promotes migration and invasion in squamous carcinoma cells","volume":"117","author":"Thomas","year":"2001","journal-title":"J. Invest. Dermatol."},{"key":"2021111818114450200_B28","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1046\/j.1523-1747.2001.01352.x","article-title":"alpha v beta 6 Integrin upregulates matrix metalloproteinase 9 and promotes migration of normal oral keratinocytes","volume":"116","author":"Thomas","year":"2001","journal-title":"J. Invest. Dermatol."},{"key":"2021111818114450200_B29","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju169","article-title":"Therapeutic targeting of integrin alphavbeta6 in breast cancer","volume":"106","author":"Moore","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"2021111818114450200_B30","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/j.1600-0625.1996.tb00134.x","article-title":"Attachment, spreading and migration of melanoma cells on vitronectin. The role of alpha V beta 3 and alpha V beta 5 integrins","volume":"5","author":"van Leeuwen","year":"1996","journal-title":"Exp. Dermatol."},{"key":"2021111818114450200_B31","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/BF02966720","article-title":"Integrin beta1-mediated invasion of human breast cancer cells: an ex vivo assay for invasiveness","volume":"10","author":"Berry","year":"2003","journal-title":"Breast Cancer"},{"key":"2021111818114450200_B32","doi-asserted-by":"crossref","first-page":"11502","DOI":"10.1016\/S0021-9258(19)38425-X","article-title":"Complete amino acid sequence of a novel integrin beta subunit (beta 6) identified in epithelial cells using the polymerase chain reaction","volume":"265","author":"Sheppard","year":"1990","journal-title":"J. Biol. Chem."},{"key":"2021111818114450200_B33","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1172\/JCI200523183","article-title":"Transcriptional activation of integrin beta6 during the epithelial\u2013mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma","volume":"115","author":"Bates","year":"2005","journal-title":"J. Clin. Invest."},{"key":"2021111818114450200_B34","doi-asserted-by":"publisher","first-page":"5889","DOI":"10.1158\/0008-5472.CAN-07-0245","article-title":"A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer","volume":"67","author":"Elayadi","year":"2007","journal-title":"Cancer Res."},{"key":"2021111818114450200_B35","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1177\/002215540205001010","article-title":"Alpha(v)beta(6) integrin-A marker for the malignant potential of epithelial ovarian cancer","volume":"50","author":"Ahmed","year":"2002","journal-title":"J. Histochem. Cytochem."},{"key":"2021111818114450200_B36","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/path.2168","article-title":"Overexpression of the alpha v beta 6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival","volume":"212","author":"Hazelbag","year":"2007","journal-title":"J. Pathol."},{"key":"2021111818114450200_B37","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1365-2559.2004.01919.x","article-title":"Immunohistochemical screening for beta6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up-regulation in pancreatic ductal adenocarcinomas in\u00a0vivo and in\u00a0vitro","volume":"45","author":"Sipos","year":"2004","journal-title":"Histopathology"},{"key":"2021111818114450200_B38","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1600-0714.1997.tb00023.x","article-title":"Changes in the expression of alpha v integrins in oral squamous cell carcinomas","volume":"26","author":"Jones","year":"1997","journal-title":"J. Oral Pathol. Med."},{"key":"2021111818114450200_B39","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1054\/bjoc.1999.1130","article-title":"Expression of alpha(v)beta6 integrin in oral leukoplakia","volume":"82","author":"Hamidi","year":"2000","journal-title":"Br. J. Cancer"},{"key":"2021111818114450200_B40","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/path.1479","article-title":"Differential expression of matrilysin-1 (MMP-7), 92 kD gelatinase (MMP-9), and metalloelastase (MMP-12) in oral verrucous and squamous cell cancer","volume":"202","author":"Impola","year":"2004","journal-title":"J. Pathol."},{"key":"2021111818114450200_B41","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S1368-8375(01)00062-8","article-title":"Tenascin and beta 6 integrin are overexpressed in floor of mouth in situ carcinomas and invasive squamous cell carcinomas","volume":"38","author":"Regezi","year":"2002","journal-title":"Oral Oncol."},{"key":"2021111818114450200_B42","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/1097-0215(20010601)92:5&lt;641::AID-IJC1243&gt;3.0.CO;2-P","article-title":"AlphaVbeta6 integrin promotes invasion of squamous carcinoma cells through up-regulation of matrix metalloproteinase-9","volume":"92","author":"Thomas","year":"2001","journal-title":"Int. J. Cancer"},{"key":"2021111818114450200_B43","doi-asserted-by":"publisher","first-page":"26533","DOI":"10.1074\/jbc.M401736200","article-title":"The integrin cytoplasmic-tail motif EKQKVDLSTDC is sufficient to promote tumor cell invasion mediated by matrix metalloproteinase (MMP)-2 or MMP-9","volume":"279","author":"Morgan","year":"2004","journal-title":"J. Biol. Chem."},{"key":"2021111818114450200_B44","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1158\/1078-0432.CCR-13-1504","article-title":"Altered microenvironment promotes progression of preinvasive breast cancer: myoepithelial expression of alphavbeta6 integrin in DCIS identifies high-risk patients and predicts recurrence","volume":"20","author":"Allen","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"2021111818114450200_B45","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/sj.onc.1205286","article-title":"Direct integrin alphavbeta6-ERK binding: implications for tumour growth","volume":"21","author":"Ahmed","year":"2002","journal-title":"Oncogene"},{"key":"2021111818114450200_B46","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1078\/0344-0338-00355","article-title":"Expression of alphav integrin family in gastric carcinomas: increased alphavbeta6 is associated with lymph node metastasis","volume":"199","author":"Kawashima","year":"2003","journal-title":"Pathol. Res. Pract."},{"key":"2021111818114450200_B47","doi-asserted-by":"publisher","first-page":"5843","DOI":"10.1158\/0008-5472.CAN-08-4410","article-title":"Targeted in\u00a0vivo imaging of integrin alphavbeta6 with an improved radiotracer and its relevance in a pancreatic tumor model","volume":"69","author":"Hausner","year":"2009","journal-title":"Cancer Res."},{"key":"2021111818114450200_B48","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/path.2745","article-title":"High-resolution in\u00a0vivo imaging of breast cancer by targeting the pro-invasive integrin alphavbeta6","volume":"222","author":"Saha","year":"2010","journal-title":"J. Pathol."},{"key":"2021111818114450200_B49","doi-asserted-by":"publisher","first-page":"4406","DOI":"10.1038\/onc.2012.460","article-title":"A human monoclonal antibody 264RAD targeting alphavbeta6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in\u00a0vivo","volume":"32","author":"Eberlein","year":"2013","journal-title":"Oncogene"},{"key":"2021111818114450200_B50","first-page":"A2659","article-title":"Identification of biomarkers to monitor the activity of STX-100, a humanized anti-\u03b1v\u03b26 antibody, in a phase 2a trial in idiopathic pulmonary fibrosis","volume":"185","author":"Violette","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2021111818114450200_B51","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/sj.cgt.7700993","article-title":"Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor","volume":"14","author":"Pameijer","year":"2007","journal-title":"Cancer Gene Ther."},{"key":"2021111818114450200_B52","first-page":"953","article-title":"Expression of the HER-2\/neu proto-oncogene in normal human adult and fetal tissues","volume":"5","author":"Press","year":"1990","journal-title":"Oncogene"},{"key":"2021111818114450200_B53","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.1200\/JCO.2007.12.1087","article-title":"Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma","volume":"25","author":"Leibovich","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"2021111818114450200_B54","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/j.1349-7006.2008.00762.x","article-title":"Integrin alpha v beta 6 mediates the potential for colon cancer cells to colonize in and metastasize to the liver","volume":"99","author":"Yang","year":"2008","journal-title":"Cancer Sci."},{"key":"2021111818114450200_B55","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/BF02967183","article-title":"Significance of alpha 9 beta 1 and alpha v beta 6 integrin expression in breast carcinoma","volume":"7","author":"Arihiro","year":"2000","journal-title":"Breast Cancer"}],"container-title":["Biochemical Society Transactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article-pdf\/44\/2\/349\/432372\/bst0440349.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article-pdf\/44\/2\/349\/432372\/bst0440349.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T12:53:09Z","timestamp":1718455989000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article\/44\/2\/349\/67583\/The-integrin-v-6-a-novel-target-for-CAR-T-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,11]]},"references-count":55,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,4,11]]},"published-print":{"date-parts":[[2016,4,15]]}},"URL":"https:\/\/doi.org\/10.1042\/bst20150249","relation":{},"ISSN":["0300-5127","1470-8752"],"issn-type":[{"value":"0300-5127","type":"print"},{"value":"1470-8752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,11]]}}}